S-Space

Browse

Author

Showing results 1 to 2 of 2

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2019-02	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial Chung, Hyun Cheol; Arkenau, Hendrik-Tobias; Lee, Jeeyun; Rha, Sun Young; Oh, Do-Youn; Wyrwicz, Lucjan; Kang, Yoon-Koo; Lee, Keun-Wook; Infante, Jeffrey R.; Lee, Sung Sook; Kemeny, Margaret; Keilholz, Ulrich; Melichar, Bohuslav; Mita, Alain; Plummer, Ruth; Smith, Denis; Gelb, Arnold B.; Xiong, Huiling; Hong, Janet; Chand, Vikram; Safran, Howard Journal for ImmunoTherapy of Cancer, Vol.7 No.1, p. 30	DOI
2019-02	Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial Chung, Hyun Cheol; Arkenau, Hendrik-Tobias; Lee, Jeeyun; Rha, Sun Young; Oh, Do-Youn; Wyrwicz, Lucjan; Kang, Yoon-Koo; Lee, Keun-Wook; Infante, Jeffrey R; Lee, Sung Sook; Kemeny, Margaret; Keilholz, Ulrich; Melichar, Bohuslav; Mita, Alain; Plummer, Ruth; Smith, Denis; Gelb, Arnold B; Xiong, Huiling; Hong, Janet; Chand, Vikram; Safran, Howard Journal for ImmunoTherapy of Cancer. 2019 Feb 04;7(1):30	view file DOI